Bayer said 2017 net income grew by 62 percent as its prescription drugs such as blood thinner Xarelto and eye medicine Eylea generated record sales.

But sales and earnings for its over-the-counter products like Aleve and its agriculture-animal health unit declined.

The Germany-based company, with about 1,600 employees in the Pittsburgh region, reported annual global sales of 35 billion euros ($42.7 billion), up 1.5 percent over 2016.

Net income was 7.3 billion euros.

Advertise with us

In the fourth quarter, net income plunged by 67 percent to 148 million euros after a charge of 455 million euros related to the U.S. tax reform bill enacted in December.

Fourth-quarter sales fell 2.6 percent to 8.6 billion euros from the prior year.

Bayer said it expects its deal to buy U.S. seed maker Monsanto to close in the second quarter.

Joyce Gannon: jgannon@post-gazette.com or 412-263-1580.